Last reviewed · How we verify
Prostaglandin E2 (Prostin)
Prostaglandin E2 (Prostin) is a Prostaglandin analog Small molecule drug developed by University Medical Centre Maribor. It is currently FDA-approved for Labor induction, Maintenance of patent ductus arteriosus in neonates, Gastric ulcer prevention and treatment. Also known as: dinoprostone.
Prostaglandin E2 (PGE2) binds to prostaglandin E receptors (EP receptors) on cell surfaces to modulate inflammation, vasodilation, and smooth muscle contraction.
Prostaglandin E2, also known as Prostin, is a small molecule that has been studied for its use in various obstetric conditions, including IUD insertion pain, induction of labor, and premature rupture of membranes at term. It is administered via vaginal dinoprostone, which is used to ripen the cervix and facilitate these procedures.
At a glance
| Generic name | Prostaglandin E2 (Prostin) |
|---|---|
| Also known as | dinoprostone |
| Sponsor | University Medical Centre Maribor |
| Drug class | Prostaglandin analog |
| Target | Prostaglandin E receptors (EP1, EP2, EP3, EP4) |
| Modality | Small molecule |
| Therapeutic area | Obstetrics/Gynecology, Neonatology, Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
PGE2 is an endogenous eicosanoid that acts as a signaling molecule through four G-protein coupled receptors (EP1-EP4). Depending on the receptor subtype and tissue context, PGE2 can promote vasodilation, inhibit platelet aggregation, enhance mucus secretion, and modulate immune responses. In clinical use, exogenous PGE2 is employed to induce labor, maintain patent ductus arteriosus in neonates, and protect gastric mucosa.
Approved indications
- Labor induction
- Maintenance of patent ductus arteriosus in neonates
- Gastric ulcer prevention and treatment
Common side effects
- Uterine contractions/cramping
- Diarrhea
- Nausea
- Fever
- Vomiting
- Abdominal pain
Key clinical trials
- Mechanical Dilation of the Cervix in a Scarred Uterus (NA)
- Cervical Ripening Before Induction of Labour at Term: a Randomised Comparison of Prostin vs Propess (PHASE3)
- What After the First Propess (PHASE2)
- Vaginal Dinoprostone Versus Isonicotinic Acid Hydrazide Prior to Diagnostic Office Hysteroscopy (NA)
- Propess Versus Prostin for Induction of Labour in Women With Term PROM (PHASE4)
- Vaginal Dinoprostone Versus Vaginal Misoprostol Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients (PHASE4)
- Vaginal Misoprostol and Dinoprostone and Isonicotinic Acid Hydrazide Prior to Copper Intrauterine Device Insertion (NA)
- Vaginal Misoprostol and Dinoprostone Prior to Copper Intrauterine Device Insertion in Women (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prostaglandin E2 (Prostin) CI brief — competitive landscape report
- Prostaglandin E2 (Prostin) updates RSS · CI watch RSS
- University Medical Centre Maribor portfolio CI
Frequently asked questions about Prostaglandin E2 (Prostin)
What is Prostaglandin E2 (Prostin)?
How does Prostaglandin E2 (Prostin) work?
What is Prostaglandin E2 (Prostin) used for?
Who makes Prostaglandin E2 (Prostin)?
Is Prostaglandin E2 (Prostin) also known as anything else?
What drug class is Prostaglandin E2 (Prostin) in?
What development phase is Prostaglandin E2 (Prostin) in?
What are the side effects of Prostaglandin E2 (Prostin)?
What does Prostaglandin E2 (Prostin) target?
Related
- Drug class: All Prostaglandin analog drugs
- Target: All drugs targeting Prostaglandin E receptors (EP1, EP2, EP3, EP4)
- Manufacturer: University Medical Centre Maribor — full pipeline
- Therapeutic area: All drugs in Obstetrics/Gynecology, Neonatology, Gastroenterology
- Indication: Drugs for Labor induction
- Indication: Drugs for Maintenance of patent ductus arteriosus in neonates
- Indication: Drugs for Gastric ulcer prevention and treatment
- Also known as: dinoprostone
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing